drugset / Trial / NCT02217514

Effects of BI 44370 TA Orally Applied as Tablets on the Pharmacokinetics of Orally Administered Midazolam Solution in Healthy Volunteers

NCT02217514

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluation of the long-term (48 h) and short-term (1 h) effects of BI 44370 BS on the pharmacokinetics of midazolam as marker of a possible inhibition of CYP 3A4; safety and tolerability.

Timeline

Start
2008-02
Primary completion
2008-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 44370 Small molecule 100 mg Oral
Subject BI 44370 Small molecule 500 mg Oral
Subject Midazolam Small molecule 2 mg Oral

Indications

No indication recorded.